Welcome to MVA’s Good Morning Meeting on “Biomarkers analysis challenges in Clinical Trials” with HalioDx.
One of the biggest challenges in immunotherapy area is to find accurately which patients will benefit from a therapy or a combination of therapies. To help drug developers getting this information, the assessment of biomarkers through clinical research studies represent a key step.
Date: Tuesday June 18th 2019
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Danmark – Ground floor
Program
|
8:30 – 9:00 |
Registration & Coffee |
|
9:00 – 9:15 |
Welcome |
|
9:15 – 9:45 |
Evaluation of immune responses in clinical phase I/II trials in tumors treated with the oncolytic peptide LTX-315 |
|
9:45 – 10:15 |
Immunogram proof of concept |
|
10:15 – 10:30 |
Q&A session |
|
10:30 – 11:00 |
Networking |
Speakers
 |
 |
|
| Vibeke Sundvold Gjerstad Translational Scientist Lytix Biopharma |
Jacques Fieschi, PhD Senior Director R&D HalioDx |
|
Arranged by:
|
In collaboration with:
|
